UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/717,738	11/20/2003	Hiroyuki Odaka	087147-0604	8700
	7590 07/11/200 LARDNER LLP	EXAMINER		
SUITE 500 3000 K STREE	T NIW	WEDDINGTON, KEVIN E		
WASHINGTON		ART UNIT	PAPER NUMBER	
			1614	
			MAIL DATE	DELIVERY MODE
			07/11/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application	on No.	Applicant(s)		
Office Action Summary		10/717,73	38	ODAKA ET AL.		
		Examiner	,	Art Unit		
		Kevin E. V	Veddington	1614		
Period fo	The MAILING DATE of this communicati r Reply	on appears on the	cover sheet with the	e correspondence a	ddress	
A SHO WHIC - Exter after - If NO - Failur Any r	DRTENED STATUTORY PERIOD FOR HEVER IS LONGER, FROM THE MAILI sions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communica period for reply is specified above, the maximum statutor et or reply within the set or extended period for reply will, beply received by the Office later than three months after the digital patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF TH CFR 1.136(a). In no evition. y period will apply and w by statute, cause the app	HIS COMMUNICATION ent, however, may a reply be ill expire SIX (6) MONTHS from lication to become ABANDO	ON. timely filed om the mailing date of this one of the NED (35 U.S.C. § 133).		
Status						
2a)⊠	Responsive to communication(s) filed or This action is FINAL . 2b) Since this application is in condition for a closed in accordance with the practice u	This action is nallowance except	for formal matters, p		e merits is	
Dispositi	on of Claims					
5)⊠ 6)⊠ 7)⊠ 8)□ Applicati	Claim(s) 9,16,18,24 and 31-36 is/are per 4a) Of the above claim(s) is/are w Claim(s) 31-34 is/are allowed. Claim(s) 9,16,18 and 24 is/are rejected. Claim(s) 35 and 36 is/are objected to. Claim(s) are subject to restriction on Papers The specification is objected to by the Ex	rithdrawn from co	nsideration.			
10) 🗌 .	The specification is objected to by the Ex The drawing(s) filed on is/are: a)[Applicant may not request that any objection Replacement drawing sheet(s) including the The oath or declaration is objected to by	accepted or b) to the drawing(s) to correction is require	ne held in abeyance. Seed if the drawing(s) is o	See 37 CFR 1.85(a). objected to. See 37 C		
Priority u	nder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice (3) Inform	e (s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-9 nation Disclosure Statement(s) (PTO/SB/08) ' No(s)/Mail Date	948)	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:			

Art Unit: 1614

Claims 9, 16, 18, 24 and 31-36 are presented for examination.

Applicants' amendment and response filed March 24, 2008 have been received and entered.

Allowable Subject Matter

Claims 31-34 are allowable.

Claim Objections

Claims 35 and 36 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 16 and 24 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Meguro et al. (4,687,777) in view of Windholz et al. (PTO-1449), all

Application/Control Number: 10/717,738 Page 3

Art Unit: 1614

of record, for reasons of record as set forth in the previous Office action dated September 24, 2007 at pages 2-3 as applied to claims 16 and 24.

Applicants' remarks regarding the prior art, Meguro et al. (4,687,777) does not teach the instant active agent, pioglitazone, used to improve or treat acidosis are not persuasive since applicants' specification discloses unexpected results in the combination of pioglitazone or a salt thereof with insulin in an animal model with NIDDM (type 2 diabetes) only. The instant specification does not teaches the any unexpected results or experimental data showing diabetic acidosis is in a mammal with type1 diabetes since the term "diabetic acidosis" incorporates type 1 and type 2 diabetes.

The rejection made under 35 USC 103(a) is adhered to.

Claims 16 and 24 are not allowed.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 9 and 18 are again rejected under 35 U.S.C. 103(a) as being unpatentable over Meguro et al. (4,687,777), of record, for reason of record as set forth in the previous Office action dated September 24, 2007 at pages 4-5 as applied to claims 9 and 18.

Applicants' remarks regarding the prior art, Meguro et al. (4,687,777) does not teach the instant active agent, pioglitazone, used to improve or treat acidosis are not persuasive since applicants' specification discloses unexpected results in the administration of pioglitazone or a salt thereof in an animal model with NIDDM (type 2 diabetes) only. The instant specification does not teaches the any unexpected results or experimental data showing diabetic acidosis is in a mammal with type1 diabetes since the term "diabetic acidosis" incorporates type 1 and type 2 diabetes.

The rejection made under 35 USC 103(a) is adhered to.

Claims 9 and 18 are not allowed.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571)272-0587. The examiner can normally be reached on 12:30 pm-9:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Kevin E. Weddington Primary Examiner Art Unit 1614

/Kevin E. Weddington/ Primary Examiner, Art Unit 1614 Application/Control Number: 10/717,738

Page 6

Art Unit: 1614